LGC Implements Sensitive Assays to Improve Drug Success

26 July 2016

Michael Naughton, Senior Scientist in the Biologicals department within Drug Development Services at LGC, discusses how the company is implementing more sensitive assays to detect low abundance biomarkers and analytes, to meet the needs of the pharmaceutical industry. Hear how the Singulex Erenna® Immunoassay Platform from MilliporeSigma enables sensitive detection of analytes at below endogenous levels, providing a unique insight into health and disease states that can aid early decision making. A case study for IL-6 is presented.